Mechanisms of Action of Ect in Parkinson's Disease: Possible Role of Pineal Melatonin

References

• Agid Y., Javoy-Agid F. Peptides and Parkinson's disease. Trends in Neurosciences 1985; 8: 30–35
   Web of Science ®Google Scholar
• Aldegunde M., Miguez I., Veira J. Effects of pinealectomy on regional brain serotonin metabolism. International Journal of Neuroscience 1985; 26: 9–13
   PubMed Web of Science ®Google Scholar
• Andersen K., Balldin J., Gottfries C. G., Granerus A. K., Modigh K., Anton-Tay F. Melatonin: effects on brain function. Advances in Biochemical Psychopharmacology 1974; 11: 315–324
   PubMedGoogle Scholar
• Anton-Tay F., Chou C., Anton S., Wurtman R. J. Brain serotonin concentrations: elevation following intraperitoneal administration of melatonin. Science 1968; 162: 277–278
   PubMed Web of Science ®Google Scholar
• Appenzeller O. O., Goss J. E. Autonomic deficits in Parkinson's disease. Archives of Neurology 1971; 24: 50–57
   PubMedGoogle Scholar
• Asnis G. Parkinson's disease, depression and ECT: A review and case study. American Journal of Psychiatry 1977; 134: 191–195
   PubMed Web of Science ®Google Scholar
• Balldin J., Eden S., Granerus A. K., Modigh K., Svanborg A., Walinder J., Wallin L. Electroconvulsive therapy in Parkinson's syndrome with “on-off” phenomenon. Journal of Neural Transmission 1980; 47: 11–21
   PubMedGoogle Scholar
• Barbeau A. Role of peptides in the pathogenesis and treatment of Parkinson's disease. Central nervous system effects of hypothalamic hormones and other peptides, R. Collu. Raven Press, New York 1979; 403–414
   Google Scholar
• Barden N., Dupont A., Labrie F., Merand Y., Rouleau D., Vaudry H., Boissier J. R. Age dependent changes in the beta-endorphin content of discrete rat brain nuclei. Brain Research 1981; 208: 209–212
   PubMed Web of Science ®Google Scholar
• Baruch P., Jouvent R., Vindreau R., Drouillon C., Widlocher D., Agid Y. Improvement of parkinsonism in ECT-treated depressed patients: Parkinson's disease or depression-related extrapyramidal disorder?. Abstracts of the World Congress of Biological Psychiatry 1985; 452: 2
   Google Scholar
• Bennett J. Striatal dopamine depletion, dopamine receptor stimulation, and GABA metabolism: Implications for the therapy of Parkinson's disease. Annals of Neurology 1986; 19: 194–197
   PubMedGoogle Scholar
• Bergstrom D., Kellar K. Effect of electroconvulsive shock on monoaminergic receptor binding sites in rat brain. Nature 1979; 278: 464–466
   PubMedGoogle Scholar
• Birau N., Schloot W. Pathological nyctohumeral rhythm of melatonin secretion in psoriasis. IRCS Medical Science 1979; 7: 400
   Google Scholar
• Bolwig T. G., Hertz M. M., Paulson O. B., Spotoft H., Rafaelson O. J. The permeability of the blood brain barrier during electrically induced seizures in man. European Journal of Clinical Investigations 1977; 7: 87–93
   PubMedGoogle Scholar
• Bradbury A. J., Kelly M. E., Smith J. A. Melatonin action in the midbrain can regulate forebrain dopamine function both behaviourally and biochemically. The pineal gland: endocrine aspects, G. M. Brown, S. D. Wainwright. Pergamon Press, Oxford 1985; 327–332
   Google Scholar
• Cotzias G. C., Tang L. C., Miller S. T., Ginos J. Z. Melatonin and abnormal movements induced by L-dopa in mice. Science 1971; 173: 450–452
   PubMed Web of Science ®Google Scholar
• Datta P. C., King M. G. Melatonin: effects on brain and behavior. Neuroscience & Biobehavioral Reviews 1978; 4: 451–458
   Web of Science ®Google Scholar
• Davidson D. L. W., Yates C. M., Mawdsley C., Pullar I. A., Wilson H. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders. Journal of Neurology Neurosurgery and Psychiatry 1977; 40: 1136–1141
   PubMed Web of Science ®Google Scholar
• De Jong P. J., Lakke J. P. W. F., Teelken A. W. CSF GABA levels in Parkinson's disease. Advances in neurology, R. G. Hassler, J. F. Christ. Raven Press, New York 1984; 427–430
   Google Scholar
• Dray A. Serotonin in the basal ganglia: Functions and interactions with other neuronal pathways. Journal of Physiology (Paris) 1981; 77: 393–403
   PubMedGoogle Scholar
• Dubocovich M. L. Melatonin is a potent modulator of dopamine release in the retina. Nature 1983; 306: 782–784
   PubMed Web of Science ®Google Scholar
• Fahn S., Snider S. R., Prasad A. L. N., Lane E., Makadon H. Normalization of brain serotonin by L-tryptophan in levodopa-treated rats. Neurology 1975; 25: 861–865
   PubMed Web of Science ®Google Scholar
• Fink M. ECT for Parkinson's disease?. Convulsive Therapy 1988; 4: 189–191
   PubMedGoogle Scholar
• Fischer A. P., Schneider E., Jacobi P., Maxion H. Effect of Melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson's syndrome. European Neurology 1974; 12: 360–368
   PubMed Web of Science ®Google Scholar
• Gershanik O. S., Heikkila R. E., Duvoisin R. C. The role of serotonin neurons in the action of L-dopa in an animal model of Parkinsonism. Neurology 1979; 29((suppl))553
   Google Scholar
• Goetz C. G., Luthe W., Tanner C. M. Autonomic dysfunction in Parkinson's disease. Neurology 1986; 36: 73–75
   PubMed Web of Science ®Google Scholar
• Govitrapong P., Murrin L. C., Ebadi M. Characterisation of dopaminergic receptor sites in bovine pineal gland. Journal of Pineal Research 1984; 1: 215–226
   PubMed Web of Science ®Google Scholar
• Holocomb H. H., Sternberg D. E., Heninger G. R. Effects of electroconvulsive therapy on mood. Parkinsonism, and tardive dyskinesia in a depressed patient: ECT and dopamine system. Biological Psychiatry 1983; 18: 865–873
   PubMedGoogle Scholar
• Hornykiewicz O. Brain neurotransmitter changes in Parkinson's disease. Movement disorders, C. D. Marsden, S. Fahn. Butterworth, Woburn, Mass 1982; 41–58
   Google Scholar
• Hurst J. H., LeWitt P. A., Bums R. S., Foster N. L., Lovenberg W. CSF dopamine-betahydroxylase activity in Parkinson's disease. Neurology 1985; 35: 565–568
   PubMed Web of Science ®Google Scholar
• Kaiya H., Tanaka T., Takeuchi K., Morita K., Adachi S., Shirakawa H., Ueki H., Namba M. Decreased level of beta-endorphin like-immunoreactivity in the Cerebrospinal fluid of patients with senile dementia of the Alzheimer's type. Life Sciences 1983; 33: 1039–1043
   PubMed Web of Science ®Google Scholar
• Kastin A. J., Viosca S., Nair R. M. G., Schally A. V., Miller M. C. Interactions between pineal, hypothalamus and pituitary involving melatonin, MSH release inhibiting factor and MSH. Endocrinology 1972; 91: 1323–1328
   PubMed Web of Science ®Google Scholar
• Kavaliers M. Pineal mediation of the thermoregulatory and behavioral activating effects of beta-endorphin. Peptides 1982; 3: 679–685
   PubMed Web of Science ®Google Scholar
• Kavaliers M., Hirst M., Teskey G. C. Ageing, opioid analgesia and the pineal gland. Life Sciences 1983; 32: 2279–2287
   PubMed Web of Science ®Google Scholar
• Kerwin R., Pycock C. GABA function and Parkinson's disease. Research progress in Parkinson's disease, F. Cliford Rose, R. Capildeo. Pitman Medical, Kent 1981; 212–218
   Google Scholar
• Klein D. C. The pineal gland: A model of neuroendocrine regulation. The Hypothalamus, S. Reichlin, R. J. Baldessarini, J. B. Martin. Raven Press, New York 1987; 303–327
   Google Scholar
• Klein D. C., Smoot R., Weller J. L., Higa S., Markey S. P., Creed G. J., Jacobowitz D. M. Lesions of the paraventricular nucleus area of the hypothalamus disrupt the suprachiasmatic-spinal cord circuit in the melatonin rhythm generating system. Brain Research Bulletin 1983; 10: 647–652
   PubMed Web of Science ®Google Scholar
• Kopp N., Claustrat B., Tappaz M. Evidence for the presence of melatonin in the human brain. Neuroscience Letters 1980; 19: 237–242
   PubMed Web of Science ®Google Scholar
• Kumar M. S. A., Besch E. L., Millard W. J., Sharp D. C., Leadem C. A. Effect of short photoperiod on hypothalamic methionine-enkephalin and LHRH content and serum beta-endorphin-like immunoreactivity (beta-end LI) levels in golden hamsters. Journal of Pineal Research 1984; I: 197–205
   Google Scholar
• Lakin M. L., Miller C. H., Statt M. L., Winters W. D. Involvement of the pineal gland and melatonin in murine analgesia. Life Sciences 1981; 29: 2543–2551
   PubMed Web of Science ®Google Scholar
• Langston J. W., Forno L. A. The hypothalamus in Parkinson disease. Annals of Neurology 1978; 3: 129–133
   PubMed Web of Science ®Google Scholar
• Lebensohn Z. M., Jenkins R. B. Improvement of Parkinsonism in depressed patients treated with ECT. American Journal of Psychiatry 1975; 132: 283–285
   PubMedGoogle Scholar
• Lehmann J. Tryptophan malabsorption in levodopa-treated parkinsonism patients: effect of tryptophan on mental disturbances. Acta Medica Scandinavica 1973; 194: 181–189
   PubMedGoogle Scholar
• Lewy A. J., Kern H. A. Effects of light on human melatonin production and the human corcadian system. Progress in Neuropsychopharmacology and Biological Psychiatry 1983; 7: 551–556
   PubMed Web of Science ®Google Scholar
• Lewy A. J., Nurnberger J. I., Wehr T. A., Pack D., Becker L. E., Powell R. L., Newsome D. A. Supersensitivity to light: possible trait marker for manic-depressive illness. American Journal of Psychiatry 1985; 142: 725–727
   PubMed Web of Science ®Google Scholar
• Lewry A. J., Wehr T. A., Gold P., Goodwin F. K. Plasma melatonin in manic-depressive illness. Catecholamines: basic and clinical frontiers, E. Usdin, I. J. Kopin, J. Barchas. Pergamon Press, New York 1979; 1173–1175
   Google Scholar
• Lewry A. J., Wehr T. A., Goodwin F. K., Newsome D. A., Rosenthal N. E. Manic depressive patients may be supersensitive to light. Lancet 1981; I: 383–384
   Google Scholar
• Lipman I. J., Boykin M. E., Flora R. E. Glucose intolerance in Parkinson's disease. Journal of Chronic Disease 1974; 27: 573–579
   PubMedGoogle Scholar
• Lynch H. J., Wang P., Wurtman R. J. Increase in rat pineal melatonin content following L-dopa administration. Life Sciences 1973; 12: 145–151
   Web of Science ®Google Scholar
• Mayeux R., Stern Y., Williams J. B., Cote L. J. The relationship of serotonin to depression in Parkinson's disease. Movement Disorders 1988; 3: 237–244
   PubMed Web of Science ®Google Scholar
• McIntyre I. M., Oxenkrug G. F. Electroconvulsive shock: effect on pineal and hypothalamic indoles. Journal of Pineal Research 1984; I: 273–279
   Google Scholar
• McIntyre I. M., Norman T. R., Marriott P. F., Burrows G. D. The pineal hormone melatonin in panic disorder. Journal of Affective Disorders 1987; 12: 203–206
   PubMed Web of Science ®Google Scholar
• Miles A., Philbrick D. R. S. Melatonin and Psychiatry. Biological Psychiatry 1988; 23: 405–425
   PubMed Web of Science ®Google Scholar
• Mindham R. H. S. Psychiatric symptoms in parkinsoniam. Journal of Neurology, Neurosurgery and Psychiatry 1970; 33: 188–189
   PubMed Web of Science ®Google Scholar
• Musacchio J. M., Juluo L., Kety S. S. Increase in rat brain tyrosine hydroxylase activity produced by electroconvulsive shock. Proceedings of the National Academy of Science, USA 1969; 63: 1117–1119
   PubMedGoogle Scholar
• Nair N. P. V., Hanharasubramanian N., Pilapil N., Thavunday J. X. Plasma melatonin rhythm in normal aging and Alzheimer's disease. Journal of Neural Transmission 1986; 21((suppl))494
   Google Scholar
• Nappi G., Petraglia F., Martignoni E., Facchineti F., Bono G., Genazzani A. R. Beta-endorphin cerebrospinal fluid decrease in untreated parkinsonian patients. Neurology 1985; 35: 1371–1374
   PubMed Web of Science ®Google Scholar
• Narabayashi H., Kondo T., Hayashi A. L-threo-3,4-dihydroxyphenylserine treatment for akinesia and freezing of parkinsonism. Proceedings of the Japanese Academy 1981; 57: 351–354
   Google Scholar
• Pang S. F., Tang F., Tang P. L. Alloxan-induced diabetes and the pineal gland: Differential effects on the levels of pineal N-acetylserotonin, pineal melatonin, and serum melatonin. Journal of Pineal Research 1985; 2: 79–84
   PubMed Web of Science ®Google Scholar
• Papavasili P. S., Cotzias G. C., Duby S. E., Steck A. J., Bell M., Lawrence W. H. Melatonin and parkinsonism. Journal of the American Medical Association 1972; 221: 88–89
   Google Scholar
• Pazo J. H. Effects of melatonin on spontaneous and evoked neuronal activity in the mesencephalic reticular formation. Brain Research Bulletin 1979; 4: 725–730
   PubMed Web of Science ®Google Scholar
• Pique L., Jegou S., Bertagna X., Javoy-Agid F., Seurin D., Proeschel M. F., Girard F., Agid Y., Vaudry H., Luton J. P. Pro-opiomelanocortin peptides in the human hypothalamus: comparative study between normal subjects and Parkinson patients. Neuroscience Letters 1985; 54: 141–146
   PubMed Web of Science ®Google Scholar
• Plummer N., Bates D. Melanocyte-stimulating hormone and Parkinsonism. Lancet 1973; I: 463–465
   Google Scholar
• Rainero I., Pinessi L. Alpha-MSH and Parkinson disease. Italian Journal of Neurological Sciences 1988; 9: 95–96
   PubMedGoogle Scholar
• Rosenstein R. E., Cardinali D. P. Melatonin increases in vivo GABA accumulation in rat hypothalamus, cerebellum, cerebral cortex and pineal gland. Brain Research 1986; 398: 403–406
   PubMed Web of Science ®Google Scholar
• Roth S. D., Mukherjee S., Sackheim H. A. Electroconvulsive therapy in a patient with mania, Parkinsonism, and tardive dyskinesia. Convulsive Therapy 1988; 4: 92–97
   PubMedGoogle Scholar
• Sack R. L., Lewy A. J., Erb D. L., Vollmer W. M., Singer C. M. Human melatonin production decreases with age. Journal of Pineal Research 1986; 3: 379–388
   PubMed Web of Science ®Google Scholar
• Sandyk R. Pineal melatonin functions: Possible relevance to Parkinson's disease. International Journal of Neuroscience, (in press a)
   Google Scholar
• Sandyk R. Pineal melatonin functions and the depression of Parkinson's disease. International Journal of Neuroscience, (in press b).
   Google Scholar
• Sandyk R. Locus coeruleus-pineal melatonin interactions and the pathogenesis of the “on-off” phenomenon associated with mood changes and sensory symptoms in Parkinson's disease. Infernational Journal of Neuroscience, (in press c)
   Google Scholar
• Sandyk R. ECT, opioid system, and motor response in Parkinson's disease. Biological Psychiatry 1936; 21: 235–226
   Google Scholar
• Sandyk R., Fisher H. Melatonin mediates the antidyskinetic effects of naloxone in tardive dyskinesia. Journal of Clinical Psychopharmcology 1989; 9: 147–148
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. Serotonin in involuntary movement disorders. International Journal of Neuroscience 1988; 42: 185–205
   PubMed Web of Science ®Google Scholar
• Sandyk R., Fisher H. Increased incidence and severity of neuroleptic-induced movement disorder in pinealectomized rats. International Journal of Neuroscience 1989; 48: 303–308
   PubMed Web of Science ®Google Scholar
• Sandyk R., Iacono R. P. The relationship of the reticular system to the primary pathoetiology of Parkinson's disease. International Journal of Neuroscience 1988; 42: 297–300
   PubMed Web of Science ®Google Scholar
• Sandyk R., Iacono R. P., Bamford C. R. The hypothalamus in Parkinson's disease. Italian Journal of Neurological Sciences 1987; 8: 227–234
   PubMedGoogle Scholar
• Sandyk R., Mukherjee S. Attenuation of reserpine-induced catalepsy by melatonin and the role of the opioid system. International Journal of Neuroscience 1989; 297–301
   PubMedGoogle Scholar
• Santamaria J., Tolosa E., Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986; 36: 1130–1133
   PubMed Web of Science ®Google Scholar
• Sawada M., Nagatsu T., Nagatsu I., Ito K., Iizuka R., Kondo T., Narabayashi H. Tryptophan hydroxylase activity in the brains of controls and Parkinsonian patients. Journal of Neural Transmission 1985; 62: 107–115
   PubMed Web of Science ®Google Scholar
• Schiffer R. B., Kurlan R., Rubin A., Boer S. Evidence for atypical depression in Parkinson's disease. American Journal of Psychiatry 1988; 145: 1020–1022
   PubMed Web of Science ®Google Scholar
• Shaw K. M., Stem G. M., Sandler M. Melatonin and metatyrosine in the treatment of parkinsonism. Advances in Neurology, D. B. Calne. Raven Press, New York 1973; 115–119
   Google Scholar
• Souetre E., Salvati E., Pringuey D., Brunet G., Savelli M., Krebs B., Darcourt G. Rythme circadien tie la melatonine dans la depression: etude transversale et longitudinale. Actual Psychiatriques 1986; 5: 88–93
   Google Scholar
• Souetre E., Salvati E., Belugou J. L., Robert P., Brunet G., Darcourt G. Antidepressant effect of 5-methoxypsoralen: A preliminary report. Psychopharmacology 1988; 95: 430–431
   PubMed Web of Science ®Google Scholar
• Sugden D., Morris R. D. Changes in regional brain levels of tryptophan,5-hydroxytryptamine, 5-hydroxyindole-acetic acid, dopamine and noradrenaline after pinealectomy in the rat. Journal of Neurochemistry 1979; 32: 1593–1594
   PubMed Web of Science ®Google Scholar
• Svennerholm L., Wallin A. A. A double-blind evaluation of electroconvulsive therapy in Parkinson's disease with “on-off’ phenomena. Acta Neurologica Scandinavica 1987; 76: 191–199
   PubMedGoogle Scholar
• Swartz C. M. Characterization of the total amount of prolactin released by electroconvulsive therapy. Convulsive Therapy 1985; I: 252–257
   Google Scholar
• Tetsuo M., Polinsky R. J., Markey S. P., Kopin I. J. Urinary 6-hydroxymelatonin excretion in patients with orthostatic hypotension. Journal of Endocrinology & Metabolism 1982; 53: 607–610
   Web of Science ®Google Scholar
• Teychenne P. F., Ziegler M. G., Lake C. R., Enna S. J. Low CSF GABA in parkinsonian patients who respond poory to therapy or suffer from the “on-off” phenomena. Annals of Neurology 1982; 11: 76–79
   PubMedGoogle Scholar
• Thompson C., Checkley S. A., Arendt J. Circadian rhythms of melatonin and cortisol during treatment with despiramine in depressed and normal subjects. Chronobiology and Psychiatric Disorders, A. Halaris. Elsevier, Amsterdam 1987; 103–116
   Google Scholar
• Trentini G. P., De Gaetani C. F., Criscuolo M., Migaldi M., Ferrari G. Pineal calcifications in different physiopathological conditions in humans. Fundamentals and Clinics in Pineal Research, G. P. Trentini, C. De Gaetani, P. Pevet. Raven Press, New York 1987; 291–304
   Google Scholar
• Vaughan G. M., McDonald S. D., Jordan R. M., Allen J. P., Bell R., Stevens E. A. Melatonin, pituitary functions and stress in humans. Psychoneuroendocrinology 1979; 4: 351–362
   PubMed Web of Science ®Google Scholar
• Vitte P. A., Harthe C., Lestage P., Claustrat B., Bobillier P. Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: A biochemical and autotardiographic study. Journal of Pineal Research 1988; 5: 437–453
   PubMed Web of Science ®Google Scholar
• Ward C., Stern G., Pratt R., McKenna P. Electroconvulsive therapy in parkinsonian patients with the “on-off” syndrome. Journal of Neural Transmission 1980; 49: 133–135
   PubMedGoogle Scholar
• Wehr T. A., Goodwin F. K. Desynchronization of circadian rhythms as possible source of manic-depressive cycles. Psychopharmacology Bulletin 1980; 16: 19–20
   Google Scholar
• Wendel O. T., Waterbury L. D., Pearce L. A. Increase in monoamine concentrations in rat brain following melatonin administration. Experientia 1974; 30: 1167–1168
   PubMedGoogle Scholar
• Wetterberg L. Melatonin in humans: Physiological and clinical studies. Journal of Neural Transmission 1978; 13(Suppl)289–310
   Google Scholar
• Wirtz-Justice A., Arendt J., Marston A. Antidepressant drugs elevate rat pineal and plasma melatonin. Experientia 1980; 36: 442–444
   PubMedGoogle Scholar
• Yudovsky S. C. Parkinson's disease, depression, and electroconvulsive therapy: A clinical and neurobiological synthesis. Comprehensive Psychiatry 1979; 20: 579–581
   PubMedGoogle Scholar
• Zisapel N., Laudon M. Inhibition by melatonin of dopamine release from rat hypothalamus: regulation of calcium entry. Brain Research 1983; 272: 378–381
   PubMed Web of Science ®Google Scholar